TY - JOUR
T1 - Unpacking trial offers and low accrual rates
T2 - A qualitative analysis of clinic visits with physicians and patients potentially eligible for a prostate cancer clinical trial
AU - Hamel, Lauren M.
AU - Dougherty, David W.
AU - Albrecht, Terrance L.
AU - Wojda, Mark
AU - Jordan, Alice
AU - Moore, Tanina F.
AU - Senft, Nicole
AU - Carducci, Michael
AU - Heath, Elisabeth I.
AU - Manning, Mark A.
AU - Penner, Louis A.
AU - Kim, Seongho
AU - Eggly, Susan
N1 - Publisher Copyright:
© 2019 by American Society of Clinical Oncology.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - PURPOSE Cancer clinical trial accrual rates are low, and information about contributing factors is needed. We examined video-recorded clinical interactions to identify circumstances under which patients potentially eligible for a trial at a major cancer center were offered a trial. METHODS We conducted a qualitative directed content analysis of 62 recorded interactions with physicians (n = 13) and patients with intermediate- or high-risk prostate cancer (n = 43). Patients were screened and potentially eligible for a trial. We observed and coded the interactions in 3 steps: (1) classification of all interactions as explicit offer, offer pending, trial discussed/not offered, or trial not discussed; (2) in interactions with no explicit offer, classification of whether the cancer had progressed; (3) in interactions classified as progression but no trial offered, identification of factors discussed that may explain the lack of an offer. RESULTS Of the 62 interactions, 29% were classified as explicit offer, 12% as offer pending, 18% as trial discussed/not offered, and 39% as trial not discussed. Of those with no offer, 57% included information that the cancer had not progressed. In 68% of the remaining interactions with patients whose cancer had progressed but did not receive an offer, reasons for the lack of offer were identified, but in 32%, no explanation was provided. CONCLUSION Even in optimal circumstances, few patients were offered a trial, often because their cancer had not progressed. Findings support professional recommendations to broaden trial inclusion criteria. Findings suggest accrual rates should reflect the proportion of eligible patients who enroll.
AB - PURPOSE Cancer clinical trial accrual rates are low, and information about contributing factors is needed. We examined video-recorded clinical interactions to identify circumstances under which patients potentially eligible for a trial at a major cancer center were offered a trial. METHODS We conducted a qualitative directed content analysis of 62 recorded interactions with physicians (n = 13) and patients with intermediate- or high-risk prostate cancer (n = 43). Patients were screened and potentially eligible for a trial. We observed and coded the interactions in 3 steps: (1) classification of all interactions as explicit offer, offer pending, trial discussed/not offered, or trial not discussed; (2) in interactions with no explicit offer, classification of whether the cancer had progressed; (3) in interactions classified as progression but no trial offered, identification of factors discussed that may explain the lack of an offer. RESULTS Of the 62 interactions, 29% were classified as explicit offer, 12% as offer pending, 18% as trial discussed/not offered, and 39% as trial not discussed. Of those with no offer, 57% included information that the cancer had not progressed. In 68% of the remaining interactions with patients whose cancer had progressed but did not receive an offer, reasons for the lack of offer were identified, but in 32%, no explanation was provided. CONCLUSION Even in optimal circumstances, few patients were offered a trial, often because their cancer had not progressed. Findings support professional recommendations to broaden trial inclusion criteria. Findings suggest accrual rates should reflect the proportion of eligible patients who enroll.
UR - http://www.scopus.com/inward/record.url?scp=85084542985&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084542985&partnerID=8YFLogxK
U2 - 10.1200/JOP.19.00444
DO - 10.1200/JOP.19.00444
M3 - Article
C2 - 31790330
AN - SCOPUS:85084542985
SN - 2688-1527
VL - 16
SP - E124-E131
JO - JCO Oncology Practice
JF - JCO Oncology Practice
IS - 2
ER -